RECRUITING

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Official Title

A Multi-Center Pilot Biomarker Study With Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Quick Facts

Study Start:2024-04-19
Study Completion:2030-04-19
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06410300

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patient older than 18 years age
  2. * Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.
  3. * Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
  4. * Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
  5. * ECOG performance status of 0-2
  6. * Life expectancy of 6 months or longer
  7. * Patient able to provide a written informed consent prior to study entry
  1. * Prior thoracic radiotherapy to chest.
  2. * Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
  3. * Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

Contacts and Locations

Study Contact

Hilary Elom, MD
CONTACT
318-816-3582
hebcq@health.missouri.edu

Principal Investigator

Bo Lu, MD
PRINCIPAL_INVESTIGATOR
Chair, Department of Radiation Oncology

Study Locations (Sites)

University of Missouri - Ellis Fischel Cancer Center
Columbia, Missouri, 65212
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
United States
University of Rochester Medical Center
Rochester, New York, 14642
United States

Collaborators and Investigators

Sponsor: Bo Lu

  • Bo Lu, MD, PRINCIPAL_INVESTIGATOR, Chair, Department of Radiation Oncology

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-19
Study Completion Date2030-04-19

Study Record Updates

Study Start Date2024-04-19
Study Completion Date2030-04-19

Terms related to this study

Additional Relevant MeSH Terms

  • Lung Cancer